
Evaluating bone health in women with oestrogen receptor positive breast cancer (ERBC) starting aromatase inhibitors
Keywords: مهار کننده آراماتاز; Oestrogen receptor positive breast cancer; Aromatase inhibitor; Osteoporosis; Fragility fracture risk; Bone mineral density; Dual X-ray absorptiometry scan